Torcetrapib’s fatal flaw was evidently not what it was thought to be.
I've seen speculation that it was:
a) Blood pressure related (and therefore unique to Torc)
b) RLT related (and therefore class related)
Now there is a possibility it is aldosterone related. Maybe. I'd want to see the paper. I still think that based upon epidemiological data there is a good bet this is class related. The epidemiological story for LDL is very clean (lower is better) - the epidemiological story for CETP is much much muddier.
Market Data 
Markets 
AI
